L
Lei Chen
Researcher at Shantou University
Publications - 15
Citations - 5927
Lei Chen is an academic researcher from Shantou University. The author has contributed to research in topics: Erlotinib & Lung cancer. The author has an hindex of 9, co-authored 14 publications receiving 5067 citations.
Papers
More filters
Journal ArticleDOI
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou,Yi-Long Wu,Gongyan Chen,Jifeng Feng,Xiaoqing Liu,Changli Wang,Shucai Zhang,Jie Wang,Songwen Zhou,Shengxiang Ren,Shun Lu,Li Zhang,Chengping Hu,Chunhong Hu,Yi Luo,Lei Chen,Ming Ye,Jian'An Huang,Xiuyi Zhi,Yiping Zhang,Qingyu Xiu,Jun Ma,Changxuan You +22 more
TL;DR: It is suggested that erlotinib is important for first-line treatment of patients with advanced EGFR mutation-positive NSCLC, and was associated with more favourable tolerability than standard chemotherapy.
Journal ArticleDOI
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
Jin Li,Shukui Qin,Jianming Xu,Jianping Xiong,Changping Wu,Yuxian Bai,Wei Liu,Jiandong Tong,Yunpeng Liu,Rui-Hua Xu,Zhehai Wang,Qiong Wang,Xuenong Ouyang,Yan Yang,Yi Ba,Jun Liang,Xiaoyan Lin,Deyun Luo,Rongsheng Zheng,Xin Wang,Guoping Sun,Liwei Wang,Leizhen Zheng,Hong Guo,Jingbo Wu,Nong Xu,Jianwei Yang,Hong-gang Zhang,Ying Cheng,Ningju Wang,Lei Chen,Zhining Fan,Piaoyang Sun,Hao Yu +33 more
TL;DR: These data show that apatinib treatment significantly improved OS and PFS with an acceptable safety profile in patients with advanced gastric cancer refractory to two or more lines of prior chemotherapy.
Journal ArticleDOI
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
Yi-Long Wu,Caicun Zhou,Chong-Kin Liam,G. Wu,Xiaoqing Liu,Z. Zhong,S. Lu,Y. Cheng,B. Han,Lei Chen,C. Huang,S. Qin,Y. Zhu,H. Pan,H. Liang,E. Li,G. Jiang,Soon Hin How,M.C.L. Fernando,Y. Zhang,F. Xia,Y.-X. Zuo +21 more
TL;DR: It is demonstrated that first-line erlotinib provides a statistically significant improvement in PFS versus GP in Asian patients with EGFR mutation-positive NSCLC (NCT01342965).
Journal ArticleDOI
Final overall survival results from a randomised, Phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
Caicun Zhou,Yi-Long Wu,Gongyan Chen,Ji Feng Feng,Xiaoqing Liu,Changli Wang,Shucai Zhang,Jian Wang,Songwen Zhou,Shengxiang Ren,Shaoyong Lu,Lin Zhang,Chengping Hu,Yi Luo,Lei Chen,Ming Ye,Jian'An Huang,Xiuyi Zhi,Yiping Zhang,Qingyu Xiu,Jun Ma,Changxuan You +21 more
TL;DR: The significant OS benefit observed in patients treated with EGFR-TKI emphasises its contribution to improving survival of EGFR mutation-positive advanced non-small-cell lung cancer patients, suggesting that erlotinib should be considered standard first-line treatment of EGfr mutant patients and EGFR -TKI treatment following first- line therapy also brings significant benefits to those patients.
Journal ArticleDOI
Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)
Lin Shen,Jin Li,Jianming Xu,Hongming Pan,Guanghai Dai,Shukui Qin,Liwei Wang,Jinwan Wang,Zhenzhou Yang,Yongqian Shu,Rui-Hua Xu,Lei Chen,Yunpeng Liu,Shiying Yu,Lilian Bu,Yongzhe Piao +15 more
TL;DR: Addition of bevacizumab to capecitabine–cisplatin in Chinese patients with advanced gastric cancer did not improve outcomes in AVATAR, and there was no difference in OS between the two arms and PFS was similar in both arms.